Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
Daiichi Sankyo Ltd.
Eligible participants will be randomly allocated to either the Experimental or Active Comparator Arm. In the Experimental Arm, participants will receive patritumab deruxtecan (HER3-DXd), given intravenously, at a dose of 5.6mg/kg every 3 weeks. In the Active Comparator Arm, participants will receive platinum-based chemotherapy for 4 cycles: pemetrexed (500mg/m^2) plus either cisplatin (75mg/m^2) or carboplatin (target area under the curve 5 [AUC5] by using the Calvert formula). Chemotherapy will be administered intravenously every 3 weeks.